SPC
SRNE

Sigma Planning Corp’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Sigma Planning Corp’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,440
Closed -$89.6K – 1499
2021
Q3 		$110K Buy
14,440
+1,110
+8% +$9.41K ﹤0.01% 1310
2021
Q2 		$129K Sell
13,330
-2,050
-13% -$16.3K ﹤0.01% 1344
2021
Q1 		$127K Buy
15,380
+3,930
+34% +$41.5K ﹤0.01% 1270
2020
Q4 		$78K Sell
11,450
-8,160
-42% -$65.5K ﹤0.01% 1164
2020
Q3 		$219K Buy
+19,610
New +$179K 0.01% 920
2019
Q3 		– Sell
-41,500
Closed -$111K – 1084
2019
Q2 		$111K Buy
41,500
+1,000
+2% +$3.6K 0.01% 953
2019
Q1 		$192K Buy
40,500
+20,250
+100% +$53.1K 0.01% 858
2018
Q4 		$49K Buy
20,250
+1,000
+5% +$3.27K ﹤0.01% 835
2018
Q3 		$85K Hold
19,250
– – 0.01% 925
2018
Q2 		$139K Buy
19,250
+4,750
+33% +$32.3K 0.01% 856
2018
Q1 		$75K Buy
+14,500
New +$103K 0.01% 835

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Sigma Planning Corp's SRNE Position: Q4 2021 in Review

Sigma Planning Corp sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2021, closing a stake of 14,440 shares — an estimated $89.6K sold.

Sigma Planning Corp first reported a position in SRNE in Q1 2018 and held it in 11 quarters. The position peaked at $219K in Q3 2020. 234 funds tracked by Wall St. Rank hold SRNE as of Q4 2021.

  • Sigma Planning Corp reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Sigma Planning Corp sold 14,440 Sorrento Therapeutics, Inc. shares in Q4 2021, an estimated $89.6K.
  • Sigma Planning Corp first reported a position in Sorrento Therapeutics, Inc. in Q1 2018 and held it in 11 quarters.
  • Sigma Planning Corp's Sorrento Therapeutics, Inc. position peaked at $219K in Q3 2020.
  • 234 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2021.

Based on Sigma Planning Corp's 13F filing for Q4 2021, filed 2 Feb 2022.